Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colchicine and Inflammation in Aortic Stenosis
Sponsor: Radboud University Medical Center
Summary
Aortic stenosis (AS) is the most common valvular heart disease in the developed world. Once symptomatic, untreated patients have a poor prognosis with five-year survival rate of 25%. Once at an advanced stage, AS will lead to the development of left ventricle hypertrophy, and eventually heart failure and death. At-present, there is no effective medical therapy for aortic stenosis. Current management of patients with AS consists of 'watchful waiting'. Valve replacement is needed when these patients (often acutely) become symptomatic. Recent studies have shown that inflammatory processes with similarities to atherosclerosis play an important role in AS. Therefore, we hypothesize that treatment with anti-inflammatory therapy, in the form of colchicine, could reduce the progression of AS. If positive, this trial will be the first to provide a potential therapeutic option for millions of people world-wide with AS.
Official title: Does Colchicine Reduce Progression of Aortic Valve Stenosis?
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2022-12-22
Completion Date
2025-12-22
Last Updated
2025-09-11
Healthy Volunteers
No
Conditions
Interventions
Colchicine
ATC: M04AC01
Placebo
Placebo tablets
Locations (1)
Radboudumc
Nijmegen, The Netherlands, Netherlands